CD180 and myelodysplastic syndrome: Similarly, there are data to suggest that CD180 may also be useful as a biomarker to indicate pharmacodynamic responses to bromodomain (BRD) inhibitors, which have shown pre-clinical efficacy in hematological malignancies such as MDS and AML.